Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for connective tissue disease-associated interstitial lung disease
ChiCTR2100046283Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pirfenidone in connective tissue disease-associated interstitial lung disease (CTD-ILD) and rheumatoid arthritis (RA), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Cytokine levels. Planned start May 2021; status: not yet recruiting.
02
Drugs
pirfenidone
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2100046283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046283.